CAJ | 학술논문

目的：研究程序化细胞死亡分子5(PDCD5)在晚期非小细胞肺癌(NSCLC)患者血清中的表达,探讨其与化疗药物敏感性的关系。方法收集经病理证实为晚期 NSCLC 患者40例作为肺癌组,体检健康者20例为正常组。肺癌组给予铂类药物联合其他化疗药物进行化疗,治疗周期为21 d,治疗2周期后进行疗效评估,分为有效组和无效组。采用ELISA 法分别检测肺癌组化疗前后及正常组血清中 PDCD5蛋白的水平,并分析其与疗效、临床特征的关系。结果正常组血清中 PDCD5蛋白的水平高于肺癌组,差异有统计学意义(P <0．05)。化疗前 PDCD5蛋白的水平有效组高于无效组,差异有统计学意义(P <0．05)。化疗后 PDCD5蛋白的水平有效组显著高于无效组,差异有统计学意义( P <0．01)。有效组化疗后 PDCD5蛋白的水平高于化疗前,差异有统计学意义(P <0．05)。无效组化疗后 PDCD5蛋白的水平低于化疗前,差异有统计学意义(P <0．05)。肺癌组血清中 PDCD5蛋白的水平与有无淋巴结转移及肿瘤的分化程度有关(P <0．05),与患者是否吸烟、性别、病理类型均无关(P>0．05)。结论晚期 NSCLC 患者血清中 PDCD5蛋白的水平有望成为化疗敏感性的预测因子,其表达水平降低可能与肺癌的发生有关,也可能为晚期 NSCLC 患者不良预后因素。
목적：연구정서화세포사망분자5(PDCD5)재만기비소세포폐암(NSCLC)환자혈청중적표체,탐토기여화료약물민감성적관계。방법수집경병리증실위만기 NSCLC 환자40례작위폐암조,체검건강자20례위정상조。폐암조급여박류약물연합기타화료약물진행화료,치료주기위21 d,치료2주기후진행료효평고,분위유효조화무효조。채용ELISA 법분별검측폐암조화료전후급정상조혈청중 PDCD5단백적수평,병분석기여료효、림상특정적관계。결과정상조혈청중 PDCD5단백적수평고우폐암조,차이유통계학의의(P <0．05)。화료전 PDCD5단백적수평유효조고우무효조,차이유통계학의의(P <0．05)。화료후 PDCD5단백적수평유효조현저고우무효조,차이유통계학의의( P <0．01)。유효조화료후 PDCD5단백적수평고우화료전,차이유통계학의의(P <0．05)。무효조화료후 PDCD5단백적수평저우화료전,차이유통계학의의(P <0．05)。폐암조혈청중 PDCD5단백적수평여유무림파결전이급종류적분화정도유관(P <0．05),여환자시부흡연、성별、병리류형균무관(P>0．05)。결론만기 NSCLC 환자혈청중 PDCD5단백적수평유망성위화료민감성적예측인자,기표체수평강저가능여폐암적발생유관,야가능위만기 NSCLC 환자불량예후인소。
Objective To investigate the expression level of programmed cell death 5(PDCD5) in advanced non-small cell lung cancer ( NSCLC), and to explore the correlation study of its sensitivity to chemotherapy drugs. Methods 40 advanced non-small cell lung cancer patients were collected and confirmed by pathological examina-tion and designated them as lung cancer group. Another 20 persons whose physical examinations were healthy were collected as normal group. Patients in lung cancer group were given platinum drugs combined with other chemother-apy drugs. The chemotherapy cycle was 21 days and curative effect evaluation was made after 2 cycles of treatment. According to efficacy they were divided into effective group and ineffective group. ELISA was used to detect the ser-um PDCD5 concentration in lung cancer group and normal control group, and its relationship with curative effect and clinical significance was analysed. Results The serum PDCD5 protein level in the normal group was higher than the lung cancer group and the difference was statistically (P < 0. 05). Before chemotherapy the serum PDCD5 protein concentration in effective chemotherapy group was higher than the ineffective group, and the difference was statistically (P < 0. 05). After chemotherapy the PDCD5 protein level difference was dramatically increased be-tween the effective group and the ineffective group, and the difference was statistically significant (P < 0. 01). Af-ter chemotherapy effective group PDCD5 protein level was higher than before, the difference was statistically signifi-cant (P < 0. 05). After chemotherapy ineffective group PDCD5 protein level was lower than before, the difference was statistically significant (P < 0. 05). PDCD5 protein level was associated with lymph node metastasis and differ-entiated degree (P < 0. 05). It was not correlated with gender, pathological type and smoking history (P > 0. 05). Conclusion PDCD5 protein level in serum of patients with advanced NSCLC is expected to be a predictor of che-mosensitivity. The down-regulation of PDCD5 expression level may be associated with the occurrence of lung cancer and may be an adverse prognostic factor of Advanced NSCLC patients.